Boston, MA 10/13/2014 (wallstreetpr) – According to reports, Pfizer Inc. (NYSE:PFE) has announced that it would present the phase-1 and phase-2 study data of the recent study that it conducted about a new vaccine candidate. The presentation will be made during IDWeek 2014.
Insights of the study:
Pfizer Inc. (NYSE:PFE) conducted a study for evaluation of tolerability, safety and immunogenicity of an investigational 4-antigen Staphylococcus aureus vaccine. The study mainly focused on its usability among adults. Complete data of PFE will be presented during the IDWeek, which had commenced on October 8, 2014 and will go on till October 12, 2014 in Philadelphia, Pennsylvania. As per the information, SA4Ag vaccine candidate named PF-06290510 is currently in phase-2 clinical trials. It was given Fast Track designation by US FDA in February 2014. Fast Track designation is nothing but a process, which is designed to expedite the review and facilitate the development in order to find serious treatments of serious conditions and meet medical needs.
Management of the company is quite hopeful about the future of this vaccine. Dr. Kathrin Jansen, Senior Vice President of the Vaccine Research and Early Development unit of PFA thinks that one of the major reasons of healthcare infections can be Staphylococcus aureus. According to him, these infections incur due to a significant burden to health care systems. No company has got success in producing a vaccine that can treat S. aureus disease, which creates an extra opportunity for Pfizer Inc. (NYSE:PFE) to regain its market leadership position. Current results of SA4Ag vaccine candidate development study are very positive, motivating and encouraging for the entire team.
Results of this study revealed that a single intramuscular injection of SA4Ag vaccine was given to 456 healthy adults 18 to 64 years randomly. Results showed that the drug was extremely well-tolerated and beneficial for all the candidates. Pfizer Inc. (NYSE:PFE) will continue to do further improvements in SA4Ag vaccine to make it more efficient and effective than past.
